Format

Send to

Choose Destination
Expert Rev Vaccines. 2007 Oct;6(5):659-65.

MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

Author information

1
Centre de Salut Pública de Castelló, Avda del Mar, 12, E 12100, Castelló, Spain. jpuigb@terra.es

Abstract

Influenza is a highly contagious respiratory disease associated with substantial morbidity and mortality in vulnerable populations, especially the elderly. Influenza viruses are unique in that they undergo small mutations and antigenic variation in their hemagglutinin and neuraminidase genes. Owing to the senescence of the immune system, the ability to mount novel immune responses may be particularly compromised in older people. Fluad (Novartis Vaccines), an MF59-adjuvanted subunit influenza vaccine, was formulated in order to achieve greater immunogenicity in those groups who need a higher protection than that brought about by conventional vaccines. This article summarizes the main characteristics of MF59-adjuvanted subunit influenza vaccine, the clinical effectiveness data that have been generated in recent years and future developments.

PMID:
17931147
DOI:
10.1586/14760584.6.5.659
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center